Story highlights Inovio Pharmaceuticals and GeneOne Life Science will start human testing of Zika vaccine

The first Zika vaccine tests will be in 40 healthy volunteers

(CNN) The first human trial of a Zika vaccine will begin soon, Inovio Pharmaceuticals said Monday.

Inovio, which is based in Plymouth Meeting, Pennsylvania, and GeneOne Life Science, which is based in Seoul, South Korea, worked together on the vaccine. They previously collaborated to create vaccines for Ebola and MERS , both of which are being tested.

The Zika vaccine, with the clinical-sounding name GLS-5700, will first be tested in 40 healthy volunteers. The first tests in humans should start in the next few weeks, Inovio said in a news release.

In the animal testing stage, the vaccine caused a strong antibody response, the company said.

It is still very early in the vaccine's development. Phase I of a vaccine trial ensures that it can be tolerated well in human subjects.